Dr. David Cunningham, MD
What this data tells you about Dr. Cunningham
Dr. David Cunningham is an urology physician in Ocala, FL, with 19 years in practice. Based on federal Medicare data, Dr. Cunningham performed 61,751 Medicare services across 3,969 unique beneficiaries.
Between the years covered by Open Payments, Dr. Cunningham received a total of $21,339 from 53 pharmaceutical and/or device companies across 349 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in urology physician. The majority of payments are classified as financial or ownership interests (royalties, licensing fees, or investment interests). Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Cunningham is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Testosterone injection | 32,200 | $0 | $0 |
| Injection, degarelix, 1 mg | 12,640 | $3 | $8 |
| Denosumab injection (Prolia/Xgeva) | 5,460 | $18 | $42 |
| BCG treatment for bladder cancer | 3,000 | $2 | $5 |
| Automated urinalysis | 1,964 | $2 | $5 |
| Office visit, established patient (30-39 min) | 1,344 | $91 | $320 |
| Contrast dye for imaging (iodine-based) | 1,225 | $0 | $1 |
| Blood draw (venipuncture) | 819 | $6 | $6 |
| Bladder ultrasound after voiding | 766 | $7 | $26 |
| Office visit, established patient (20-29 min) | 407 | $61 | $227 |
| Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 402 | $1 | $3 |
| Chronic care management, first 20 min/month | 273 | $48 | $159 |
| Simple timed assessment of bladder emptying | 239 | $10 | $33 |
| Drug injection, under skin or into muscle | 170 | $10 | $35 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 150 | $132 | $336 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 127 | $25 | $81 |
| X-ray of abdomen, 1 view | 124 | $21 | $60 |
| New patient office visit (45-59 min) | 118 | $118 | $422 |
| Instillation of anti-cancer drug into bladder | 84 | $65 | $219 |
| Mri scan of pelvis before and after contrast | 32 | $135 | $354 |
| Injection, garamycin, gentamicin, up to 80 mg | 29 | $2 | $3 |
| Simple insertion of temporary bladder tube | 28 | $47 | $156 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 28 | $15 | $57 |
| Hospital follow-up visit, moderate complexity | 23 | $64 | $179 |
| Diagnostic exam of bladder and urethra using an endoscope | 21 | $172 | $610 |
| Ultrasound scan of pelvic region through rectum | 19 | $26 | $65 |
| Biopsy of prostate gland | 18 | $106 | $612 |
| Initial hospital admission, moderate complexity | 15 | $106 | $341 |
| Shock wave crushing of kidney stones | 13 | $455 | $1,460 |
| Ct scan of abdomen and pelvis before and after contrast | 13 | $206 | $533 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Payments are distributed across multiple categories with no single dominant type.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Cunningham is a mixed practice specialist, with above-average Medicare volume (top 1% in FL), and high industry engagement (mixed engagement, top 11%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Cunningham experienced with testosterone injection?
Does Dr. Cunningham receive payments from pharmaceutical companies?
How do Dr. Cunningham's costs compare to other urology physicians in Ocala?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology